MASH represents a progressive stage of fatty liver disease, characterized by fat accumulation in the liver alongside inflammation and damage that may culminate in fibrosis, cirrhosis, and ultimately liver failure. The condition is tightly linked with the metabolic syndrome epidemic, including obesity and type 2 diabetes, posing an increasing global public health challenge. Despite the urgency, effective treatment options remain limited, with only modestly effective therapies currently available that do not fully reverse liver damage.

The research journey that led to this novel hypothesis began serendipitously during a separate study focusing on kidney injury associated with diabetes. Researchers administered formoterol to rodents with diabetic kidney disease and observed not only improvements in renal health but also an unexpected reduction in liver fat accumulation. This surprising collateral benefit ignited further investigation into the potential hepatic benefits of beta-2 adrenergic receptor agonism.

Delving deeper, the MUSC team employed a dietary mouse model designed to mimic MASH’s pathophysiology by inducing fatty liver disease through a high-fat diet. Subsequent treatment with formoterol yielded a remarkable reversal of fatty liver pathology, demonstrating improvements across histologic, ultrastructural, and functional parameters. These findings signaled a breakthrough, highlighting the possible restorative capabilities of this class of drugs on metabolic liver injury.

Exploring the mechanistic underpinnings, the study revealed that formoterol promotes mitochondrial biogenesis — a process invigorating the number and function of mitochondria within liver cells. As mitochondria serve as the powerhouse of the cell, enhancing their biogenesis and efficiency has profound implications for cellular metabolism and recovery from injury. By revving up mitochondrial function, formoterol appears to restore metabolic homeostasis and mitigate the progressive damage typical of MASH.

Complementing animal model insights, a retrospective review of patients using beta-2 agonists for respiratory conditions revealed clinically significant associations: those individuals exhibited reduced incidence of liver-related outcomes such as cirrhosis and overall mortality. While observational, these data provide crucial translational evidence suggesting the therapeutic potential of beta-2 agonists beyond pulmonary indications.

Currently, two drugs—resmetirom and semaglutide—have received approval to manage MASH, primarily improving liver markers but with limited reversibility of established damage and associated adverse effects. Unlike these agents, formoterol demonstrated the capacity to not merely slow disease progression but actively reverse damage, marking a paradigm shift in therapeutic strategy.

Given formoterol’s longstanding clinical use and well-characterized safety profile in respiratory disease contexts, its repositioning as a metabolic therapy could expedite development timelines and regulatory pathways. Dr. Joshua Lipschutz, leading this pioneering research, emphasizes the efficiency of drug repurposing: leveraging an already approved medication offers a pragmatic and expedient approach to addressing unmet needs in metabolic disease treatment.

Interestingly, the initial clinical trial underway targets diabetic kidney disease, reflecting the intersecting pathophysiology shared with MASH. Over 60% of patients with diabetic nephropathy concurrently suffer from MASH, driven by common mechanisms of metabolic dysfunction. Thus, this trial effectively serves a dual purpose, potentially unveiling benefits for two life-threatening diabetic complications within a single study framework.

Despite these encouraging developments, pivotal questions remain. The MASH-related data largely originate from murine models, and whilst human retrospective analyses are supportive, causality has yet to be established. Determining optimal dosing regimens for metabolic indications, clarifying route-of-administration efficacy (inhaled versus systemic), and evaluating the sustainability of therapeutic benefits over time are critical next steps in research.

Dr. Lipschutz cautions that no pharmacological agent is without risk: “Anything strong enough to do good can do bad.” This apt reminder underscores the imperative for thorough clinical evaluation to balance efficacy with safety as formoterol’s potential expands beyond its traditional scope.

Advancing through rigorously designed clinical trials, the scientific community awaits confirmation of these groundbreaking preclinical observations. Should the trials prove successful, the repurposing of formoterol would herald a new, cost-effective, and relatively safe treatment option for patients burdened by metabolic liver disease and diabetic kidney pathology.

Collectively, this research exemplifies the power of cross-disciplinary exploration, revealing how insights from nephrology and respiratory medicine can unexpectedly converge to unlock therapeutic innovations in hepatology. The possibility that a decades-old asthma medication might resolve complex metabolic disorders provides a beacon of hope and a clarion call for the continued pursuit of novel drug repurposing strategies in medical science.

Subject of Research: Animals

Article Title: Beta 2 adrenergic receptor agonists as a treatment for metabolic dysfunction-associated steatohepatitis (MASH)

News Publication Date: 22-Mar-2026

Web References: 10.1038/s44324-026-00108-2

Image Credits: Medical University of South Carolina

Keywords: Fatty liver disease, MASH, metabolic dysfunction, beta-2 adrenergic receptor agonist, formoterol, mitochondrial biogenesis, diabetic kidney disease, drug repurposing, liver transplantation, asthma medication

The liver’s ability to regenerate after injury is among the most remarkable feats of human biology. Yet, chronic injuries such as those caused by alcohol abuse, metabolic syndromes, and drug-induced toxicity trigger maladaptive repair mechanisms. Hepatic stellate cells, typically quiescent and vitamin A-rich in a healthy environment, become activated upon injury, transforming into myofibroblast-like cells that secrete extracellular matrix (ECM) components excessively. The resulting fibrotic scar tissue stiffens the liver, disrupting its intricate architecture and culminating in irreversible cirrhosis. Although liver transplantation remains the definitive treatment at late disease stages, it is plagued by donor shortages and complex complications, underscoring the urgent need for alternative therapeutic strategies.

Addressing this critical gap, the team at Science Tokyo devised an organoid system, termed iPSC-derived hepatocyte–stellate cell surrounding organoid (iHSO), which recapitulates native liver microenvironments more accurately than previous in vitro models. By differentiating human iPSCs into hepatocyte-like cells (iPS-Heps) and hepatic stellate-like cells (iPS-HSCs), then co-culturing them to form spheroids where stellate cells envelop hepatocytes, the system mimics the liver’s architectural and functional anatomy. This configuration allows direct observation of cellular signaling pathways governing repair and fibrogenesis, a feat impossible in monotypic cultures or animal surrogates.

A pivotal revelation from this model is the dualistic communication between stellate cells and hepatocytes mediated by the adhesion molecule ICAM-1 and cytokine interleukin-1β (IL-1β). The iHSO demonstrated that quiescent iPS-HSCs sustain a cytokine-rich environment that promotes hepatocyte proliferation via the ICAM-1–IL-1β axis, highlighting a supportive stellate cell phenotype in liver regeneration. This intricate signaling relationship elucidates how HSCs can act both as protectors during tissue repair and as drivers of fibrosis when dysregulated, providing critical insights into temporal therapeutic targeting.

Moreover, the iHSO exhibited robust responses to hepatotoxic insult, exemplified by exposure to acetaminophen, a common analgesic known to induce liver injury at high doses. The organoids mirrored pathophysiological injuries seen in vivo, including hepatocyte damage and subsequent stellate cell activation. This injury modeling capacity validates the iHSO as a valuable experimental platform for investigating drug-induced liver injury mechanisms and screening potential hepatoprotective agents, bridging a vital translational gap.

Chronic liver disease constitutes a burgeoning global health crisis, with over four million adults afflicted in the United States alone, and rising incidence rates documented in countries like Japan due to lifestyle and metabolic factors. Despite increased awareness, therapeutic options capable of halting or reversing fibrosis before catastrophic liver failure remain elusive. The human-based iHSO organoid presents a paradigm shift by offering a scalable, physiologically relevant tool for dissecting fibrosis evolution and for accelerating the discovery of anti-fibrotic drugs with greater predictive validity than existing animal models.

Beyond pathological applications, the organoid system opens new avenues in regenerative medicine. Understanding stellate cell heterogeneity — from quiescence to activation states — and their influence on hepatocyte survival and proliferation sets the stage for engineering next-generation bioartificial livers. Such constructs could one day supplement or replace conventional transplants, mitigating immunological rejection risks and donor scarcity.

The research team, led by Professors Sei Kakinuma and Yasuhiro Asahina alongside Assistant Professor Masato Miyoshi and graduate student Tomohiro Mochida, showcases how sophisticated in vitro models can powerfully simulate in vivo biology. Their findings, published in September 2025’s issue of Stem Cell Reports, underscore the transformative potential of organoid platforms in resolving complex cell-to-cell communication pathways essential to liver homeostasis and pathology.

This study not only validates the iHSO as a human-relevant model for liver fibrosis research but also spotlights ICAM-1 and IL-1β as promising molecular targets. Future therapeutic strategies might exploit these pathways to modulate stellate cell behavior, fine-tuning the balance between repair and fibrosis. Such interventions could forestall progression to cirrhosis, reducing the global burden of liver disease and diminishing the reliance on transplantation.

The Institute of Science Tokyo, born from the union of Tokyo Medical and Dental University and Tokyo Institute of Technology, reflects a forward-looking mission to harness fundamental and translational science in advancing human health. With the iHSO model, they have laid a solid foundation for future exploration of hepatic diseases, offering hope that one day, chronic liver injuries will be manageable and even reversible.

In sum, this pioneering organoid system provides a vital, human-based window into the cellular dynamics underlying chronic liver diseases. It redefines experimental possibilities in fibrosis research, opening pathways to innovative drug development and regenerative therapies. As the global community grapples with the rising incidence of liver pathologies, such scientific innovations stand to chart a new course toward addressing one of medicine’s most daunting challenges.

Subject of Research: Cells

Article Title: Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids

News Publication Date: 18-Sep-2025

Web References:
https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)00246-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213671125002462%3Fshowall%3Dtrue

References:
Kakinuma S, Asahina Y, Miyoshi M, Mochida T, et al. Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids. Stem Cell Reports. 2025 Sep 18. DOI: 10.1016/j.stemcr.2025.102642

Image Credits: Institute of Science Tokyo

Keywords: Liver damage, Diseases and disorders, Medical treatments, Clinical medicine, Health and medicine